2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 580

Lupus Nephritis Flares Precipitated By Switching From Mycophenolate Mofetil to Azathioprine in Pre-Pregnancy Planning
Abstract Number: 886

Lupus Neutrophil Extracellular Traps Render High Density Lipoprotein Oxidized and proatherogenic
Abstract Number: 623

Lupus Patients Have a High Prevalence Of Abnormalities On Resting Electrocardiogram That Are Associated With Increased Risk For Cardiovascular Events
Abstract Number: 1624

Lupus Risk Alleles With High Ethnic Variability Worldwide Are Associated With Renal Disease In Hispanic Patients
Abstract Number: 1610

Lymphoablation Including B Cell Depletion and Autologous Hematopoietic Stem Cell Transplantation Leads To Long Remissions In Treatment-Resistant Systemic Lupus Erythematosus Patients
Abstract Number: 1976

Magnetic Resonance Imaging-Assessment Of Early Response To Certolizumab Pegol In Rheumatoid Arthritis: A Randomized, Double-Blind, Placebo-Controlled Phase IIIb Study Applying Magnetic Resonance Imaging At Week 0, 1, 2, 4, 8 and 16
Abstract Number: 302

Maintenance Of Efficacy and Safety Of Ustekinumab In Patients With Active Psoriatic Arthritis Despite Prior Conventional Nonbiologic and Anti-TNF Biologic Therapy: 1‑year Results Of a Phase 3, Multicenter, Double-Blind, Placebo-Controlled Trial
Abstract Number: 1570

Maintenance Therapy With Taclorimus and Mizoribine Pulse In SLE
Abstract Number: 750

Maintenance Treatment In Childhood Granulomatosis With Polyangiitis
Abstract Number: 195

Major Cost Savings Associated With Reduced Biologic Dosing Frequency In Inflammatory Arthritis
Abstract Number: 327

Major Differences In The Pattern Of Joint Swelling and Tenderness In a Large Psoriatic Arthritis Cohort – Results From An Exploratory Hierarchical Cluster Analysis
Abstract Number: 1879

Major Histocompatibility Complex Class I Molecules Contribute To Behçet’s Disease Risk Through Both Innate and Adaptive Immune Interactions
Abstract Number: 2504

Male Children With Higher SLE Disease Activity In An US Cohort
Abstract Number: 719

Mammalian Target Of Rapamycin (mTOR) Skews T Cell Lineage Development In Systemic Lupus Erythematosus (SLE)
Abstract Number: 362

Management Of Hyperlipidemia In Patients With RA: Results From The Corrona Certain Study

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].